drugset / Trial / NCT02667418
Optimal Treatment for Recurrent Clostridium Difficile
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine whether fidaxomicin and vancomycin followed by taper and pulse vancomycin treatment are superior to standard vancomycin treatment for the treatment of recurrent Clostridium difficile infection.
Timeline
- Start
- 2016-02-19
- Primary completion
- 2024-08-07
- Completion
- 2024-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fidaxomicin | Other / unclassified | 200 mg | Oral |
| Subject | Vancomycin | Other / unclassified | 125 mg | Oral |